Research presented at the 2026 American Urological Association Annual Meeting reveals progress in bladder cancer treatment and prevention. Key findings include an immunotherapy drug, durvalumab, combined with standard BCG treatment, which delays disease progression and helps patients avoid bladder removal surgery. Studies also link air pollution and e-cigarette use to increased bladder cancer risk, especially among non-smokers and younger patients. These insights pave the way for more personalized approaches to bladder cancer care and prevention.
The Law Offices of Howard G. Smith has issued a reminder for investors in Stellantis, United Homes Group, LKQ Corporation, and Globant about upcoming deadlines to file lead plaintiff motions in securities fraud class actions. These lawsuits allege th...
US stock markets declined on Friday due to rising oil prices and a bond market sell-off, which increased fears of interest rate hikes by the Federal Reserve. The 10-year Treasury yield hit its highest level in a year, and traders now expect no rate c...
DexCom outlined its long-term growth vision, expecting over 10% annual organic revenue growth through 2030. The company aims for a 67-69% adjusted gross profit margin and a 29-30% adjusted operating profit margin by 2030. DexCom also approved a new $...
Trasteel Holding S.A. and Al Qalaa International Group have established a 50-50 joint venture named QTrasteel to enhance trading, project development, and industrial services across the Middle East and North Africa (MENA) region. This partnership lev...
Globant reported Q1 adjusted EPS of $1.50, matching expectations, and revenue of $607.1 million, slightly above estimates. The company's AI Pods contributed significantly to growth, with annual recurring revenue reaching $32.8 million. Despite a slig...
